hydralazine has been researched along with Renal Insufficiency, Chronic in 15 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We present a case report of a premenopausal patient with hydralazine-associated amenorrhea." | 8.98 | Hydralazine-associated Amenorrhea in a Premenopausal Patient With Chronic Kidney Disease: A Case Report and Review of Literature. ( Al-Makki, A; Allspaw, A; Shepler, BM; Yeboah, KA, 2018) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 8.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 5.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| " We present a case report of a premenopausal patient with hydralazine-associated amenorrhea." | 4.98 | Hydralazine-associated Amenorrhea in a Premenopausal Patient With Chronic Kidney Disease: A Case Report and Review of Literature. ( Al-Makki, A; Allspaw, A; Shepler, BM; Yeboah, KA, 2018) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 4.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| " Among blacks with hypertensive chronic kidney disease, neither PM (bedtime) dosing of once-daily antihypertensive nor the addition of drugs taken at bedtime significantly reduced nocturnal BP compared with morning dosing of antihypertensive medications." | 2.78 | A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. ( Agodoa, LY; Appel, LJ; Bakris, GL; Charleston, J; Contreras, G; Gabbai, F; Greene, T; Hiremath, L; Jamerson, K; Kendrick, C; Kusek, JW; Lash, JP; Lea, J; Miller, ER; Phillips, RA; Rahman, M; Rostand, S; Toto, R; Wang, X; Wright, JT, 2013) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 1.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| "Renal fibrosis was increased 2." | 1.42 | A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression. ( Bin, W; Cao, W; Hou, FF; Li, A; Su, Z; Wang, L; Wilcox, CS; Zhou, Z, 2015) |
| "Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats." | 1.40 | Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats. ( Ayajiki, K; Funai, A; Kobuchi, S; Matsumura, Y; Ohkita, M; Suzuki, R; Tanaka, R; Tsutsui, H; Yazawa, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Larkin, BP | 1 |
| Nguyen, LT | 1 |
| Hou, M | 1 |
| Glastras, SJ | 1 |
| Chen, H | 1 |
| Faiz, A | 1 |
| Chen, J | 1 |
| Wang, R | 1 |
| Pollock, CA | 1 |
| Saad, S | 1 |
| Chiang, CH | 1 |
| Chen, C | 1 |
| Fang, SY | 1 |
| Lin, SC | 1 |
| Chen, JW | 2 |
| Chang, TT | 2 |
| Hayashi, K | 1 |
| Shimokawa, T | 1 |
| Yamagata, M | 1 |
| Yoneda, K | 1 |
| Fujita, Y | 1 |
| Ichikawa, D | 1 |
| Sugaya, T | 1 |
| Ohata, K | 1 |
| Tanabe, J | 1 |
| Inoue, K | 1 |
| Hoshino, S | 1 |
| Togo, T | 1 |
| Watanabe, M | 1 |
| Kimura, K | 1 |
| Shibagaki, Y | 1 |
| Kamijo-Ikemori, A | 1 |
| Yeboah, KA | 1 |
| Allspaw, A | 1 |
| Al-Makki, A | 1 |
| Shepler, BM | 1 |
| Sogawa, Y | 1 |
| Nagasu, H | 1 |
| Itano, S | 1 |
| Kidokoro, K | 1 |
| Taniguchi, S | 1 |
| Takahashi, M | 1 |
| Kadoya, H | 1 |
| Satoh, M | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Kobuchi, S | 1 |
| Tanaka, R | 1 |
| Funai, A | 1 |
| Suzuki, R | 1 |
| Yazawa, M | 1 |
| Tsutsui, H | 1 |
| Ohkita, M | 1 |
| Ayajiki, K | 1 |
| Matsumura, Y | 1 |
| Cao, W | 1 |
| Li, A | 1 |
| Wang, L | 1 |
| Zhou, Z | 1 |
| Su, Z | 1 |
| Bin, W | 1 |
| Wilcox, CS | 1 |
| Hou, FF | 1 |
| Ueda, M | 1 |
| Uchimura, K | 1 |
| Narita, Y | 1 |
| Miyasato, Y | 1 |
| Mizumoto, T | 1 |
| Morinaga, J | 1 |
| Hayata, M | 1 |
| Kakizoe, Y | 1 |
| Adachi, M | 1 |
| Miyoshi, T | 1 |
| Shiraishi, N | 1 |
| Kadowaki, D | 1 |
| Sakai, Y | 1 |
| Mukoyama, M | 1 |
| Kitamura, K | 1 |
| Yee, J | 1 |
| Tampe, B | 1 |
| Steinle, U | 1 |
| Tampe, D | 1 |
| Carstens, JL | 1 |
| Korsten, P | 1 |
| Zeisberg, EM | 1 |
| Müller, GA | 1 |
| Kalluri, R | 1 |
| Zeisberg, M | 1 |
| Nishihara, M | 1 |
| Takesue, K | 1 |
| Hirooka, Y | 1 |
| Rahman, M | 1 |
| Greene, T | 1 |
| Phillips, RA | 1 |
| Agodoa, LY | 1 |
| Bakris, GL | 1 |
| Charleston, J | 1 |
| Contreras, G | 1 |
| Gabbai, F | 1 |
| Hiremath, L | 1 |
| Jamerson, K | 1 |
| Kendrick, C | 1 |
| Kusek, JW | 1 |
| Lash, JP | 1 |
| Lea, J | 1 |
| Miller, ER | 1 |
| Rostand, S | 1 |
| Toto, R | 1 |
| Wang, X | 1 |
| Wright, JT | 1 |
| Appel, LJ | 1 |
| LICHTIG-DINULESCU, E | 1 |
| BOROS, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| African American Study of Kidney Disease and Hypertension ABPM Pilot Study[NCT00582777] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Effect of Potassium Losartan With Bedtime Dosing on Chronic Kidney Disease Patients With Nondipping Blood Pressure Pattern[NCT03603938] | 189 participants (Anticipated) | Interventional | 2018-11-01 | Not yet recruiting | |||
| Prognostic Effect of Isolated Nocturnal Hypertension Pattern With Nondialysis CKD[NCT03604003] | 252 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydralazine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Hydralazine-associated Amenorrhea in a Premenopausal Patient With Chronic Kidney Disease: A Case Report and Review of Literature.
Topics: Adult; Amenorrhea; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Premenopause; | 2018 |
1 trial available for hydralazine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
13 other studies available for hydralazine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.
Topics: Albuminuria; Animals; Diet, High-Fat; Disease Models, Animal; Fibrosis; Hydralazine; Inflammation; K | 2022 |
Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Enzyme Inhibitors; Fibrosis; Humans; Hydralazine; Inflammation; Kidney | 2023 |
Hydralazine improves ischemia-induced neovasculogenesis via xanthine-oxidase inhibition in chronic renal insufficiency.
Topics: Allopurinol; Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; Enzyme Inhibitors; H | 2020 |
Inhibition of α
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blister; Disease Models, Animal; Disease Progressi | 2021 |
Angiotensin II type 1a receptor loss ameliorates chronic tubulointerstitial damage after renal ischemia reperfusion.
Topics: Angiotensin II; Animals; Blood Pressure; Hydralazine; Ischemia; Kidney; Male; Mice; Mice, Knockout; | 2021 |
The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice.
Topics: Aldosterone; Animals; Antihypertensive Agents; Disease Models, Animal; Endothelium; Fibrosis; Humans | 2018 |
Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Autonom | 2014 |
A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression.
Topics: Analysis of Variance; Animals; Blotting, Western; Brain; Disease Models, Animal; Disease Progression | 2015 |
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
PGX: Pharmacogenomics During Generation X.
Topics: Anticoagulants; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heart Failure; H | 2016 |
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Animals; CpG Islands; Dioxygenases; D | 2017 |
Renal denervation enhances GABA-ergic input into the PVN leading to blood pressure lowering in chronic kidney disease.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Denervation; Disease Models, Animal; Eating; GABAe | 2017 |
[Acute renal insufficiency during hydrazinophthalazine therapy of chronic renal insufficiency].
Topics: Acute Kidney Injury; Humans; Hydralazine; Kidney Failure, Chronic; Renal Insufficiency, Chronic | 1957 |